title: Experience with poorly myelosuppressive chemotherapy schedules for advanced myeloma. The Cooperative Group of Study and Treatment of Multiple Myeloma.
abstract: In a multicentre study, 83 patients with advanced and previously uniformly treated multiple myeloma (MM) were randomised between cyclophosphamide (600 mg m-2) and epirubicin (70 mg m-2), administered every 3 weeks for three courses and both associated with prednisone and interferon-alpha2b. Both regimens were administered on an outpatient basis and had low haematological toxicity. Clinical results were similar. Overall response rate (43%) and median response and survival (5.9 and 14.1 months respectively) compare well with those obtained with more aggressive chemotherapy schedules.
authors.affiliation: Medicina Interna ed Oncologia Medica, Universita and Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S. Matteo, Pavia, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Brugnatelli
authors.forename: A
authors.initials: A
authors.lastname: Riccardi
authors.forename: G
authors.initials: G
authors.lastname: Ucci
authors.forename: O
authors.initials: O
authors.lastname: Mora
authors.forename: L
authors.initials: L
authors.lastname: Barbarano
authors.forename: N
authors.initials: N
authors.lastname: Piva
authors.forename: L
authors.initials: L
authors.lastname: Piccinini
authors.forename: C
authors.initials: C
authors.lastname: Bergonzi
authors.forename: A
authors.initials: A
authors.lastname: De Paoli
authors.forename: M
authors.initials: M
authors.lastname: Di Stasi
authors.forename: E
authors.initials: E
authors.lastname: Rinaldi
authors.forename: G
authors.initials: G
authors.lastname: Trotti
authors.forename: M
authors.initials: M
authors.lastname: Petrini
authors.forename: E
authors.initials: E
authors.lastname: Ascari
mesh_terms: D000328:Adult; D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004334:Drug Administration Schedule; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D009196:Myeloproliferative Disorders / Q000139:chemically induced; D010440:Peptichemio / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D011994:Recombinant Proteins; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D018906:Antineoplastic Agents, Alkylating; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D015251:Epirubicin; D014750:Vincristine; D003520:Cyclophosphamide; D010440:Peptichemio; D008558:Melphalan; D011241:Prednisone